Andera Partners Research
Investment Thesis
Andera Partners is a leading independent European private equity firm headquartered in Paris, with over 20 years of history and roughly €6 billion in assets under management. The firm's signature phrase, "The Power of And," reflects its core conviction: that companies grow best when management teams have the right partners alongside them, not just capital. Andera operates as a multi-strategy platform, running six distinct investment vehicles that together span the full spectrum from early-stage life-sciences venture investing through growth equity, mezzanine debt, and green infrastructure. The firm positions itself as a hands-on partner, offering support well beyond financing: acquisition strategy, digitalisation, CSR/ESG, networking, internationalisation, human-capital strengthening, operational improvement, and financing structuring.
Sector Focus
Andera's activity spans six named strategies, each with its own sector emphasis:
- andera Life Sciences — therapeutic and medical innovation (biotech, medtech) in Europe and the US
- andera Infra (plus the smaller Terra Nea vehicle) — green/renewable infrastructure, primarily in France
- andera Expansion — growth capital for European SMEs (€10m–€500m revenue)
- andera MidCap — development capital for European mid-caps
- andera Acto — sponsorless mezzanine financing across industrials, services, travel tech, security, legal/compliance, and healthcare services
- andera Co-Invest — equity co-investment alongside the other strategies
Beyond life sciences and infrastructure, the portfolio is broadly generalist and industry-agnostic, covering industrials and manufacturing, travel technology, security and compliance software, legal tech, medical imaging groups, HR and outsourcing services, and real estate/asset management.
Stage Focus
Andera does not invest at the classic pre-seed/seed venture stages. Its strategies map instead to growth equity, buyout-adjacent development capital, and mezzanine/debt-like structures, plus venture-stage biotech investing within andera Life Sciences:
- andera Life Sciences: growth-stage biotech/medtech equity, €15m–€60m
- andera Infra: infrastructure equity, €10m–€40m (Terra Nea: €1m–€5m)
- andera Expansion: growth equity for SMEs, €15m–€40m
- andera MidCap: development capital for mid-caps, €40m–€120m
- andera Acto: mezzanine financing, €10m–€150m
- andera Co-Invest: co-investment equity, €10m–€20m
Check Size
Typical equity/financing ticket across the platform ranges from roughly €1m (Terra Nea) to €150m (andera Acto mezzanine), with the bulk of activity concentrated in the €10m–€120m band depending on strategy.
Lead Tendency
Andera is typically the lead or sole institutional sponsor on its deals — portfolio announcements consistently describe the firm "investing in," "acquiring," or "leading" financings for portfolio companies (e.g., leading a $20M Series D in Rivermark Medical, leading Andera Acto's investment in exceet Card Group).
Recent Activity
Andera has been highly active through 2026, deploying across all six strategies:
- September 2026: Acquired Sotralu Group (andera Expansion) and Sabena Aerospace (MRO)
- June 2026: andera Acto invested in Plasseraud IP
- May 2026: Led a $20M Series D financing in Rivermark Medical; Andera Infra sold its stake in Nostrum Group to IREN (NASDAQ-listed)
- February 2026: andera Acto invested in exceet Card Group; press coverage cited ~€10bn platform AUM and 22 investment transactions for the year
- January 2026: Invested in Alveus Therapeutics and Spiro Medical
- April 2026: Portfolio company Tubulis was acquired by Gilead in an oncology ADC deal
- July 2026: Announced a record €430M fundraise for Andera Expansion IV
Fund status: actively deploying across all strategies, with a steady cadence of new platform investments, bolt-on acquisitions, and exits.
Portfolio Highlights
Andera's cumulative portfolio spans 377+ companies over more than 20 years of investing. Notable recent exits include Tubulis (acquired by Gilead, 2026), Nostrum Group (sold to IREN, 2026), and historical exits including Axonics (acquired by Boston Scientific) and several other life-sciences names (Poxel, Vivoryon, JenaValve, LogicBio, Allecra). Current life-sciences names include Inventiva, Abivax, Bioptimus (an AI foundation model for biology), Mineralys Therapeutics, Nouscom, and Kestra Medical Technologies. Industrial, services, and infrastructure names include Lhyfe (green hydrogen), Tecnikabel, Klubb Group, Sogetrel, and Ayming.
Team
Andera Partners has a large, multi-office team of roughly 130+ professionals organized by strategy. Key partners include:
- Raphaël Wisniewski, Partner
- Thierry Hercend, Venture Partner (Life Sciences)
- Stéphane Bergez, Partner, Head of Andera Acto
- Olivier Litzka, Partner
- Sofia Ioannidou, Partner
- Jan Van den Bossche, Partner
- Vincent Bazzocchi, Partner
- François-Xavier Mauron, Partner
- Laurent Tourtois, Partner
- Alexander Cuniasse, Partner
- Louis Hamon, Partner
- Sylvain Charignon, Partner
- Antoine Le Bourgeois, Partner
- David Robin, Partner
- Léopold Brichard, Partner
Decision Process
Andera runs a formal, multi-strategy investment-committee process typical of an institutional European PE platform, with dedicated leadership per strategy (e.g., Stéphane Bergez as Head of Andera Acto) rather than a solo-GP or informal partnership model.
Founder Preferences
Andera favors experienced management teams at companies with proven revenue and clear paths to scale — whether that is a biotech team with clinical/regulatory expertise, an SME founder-owner seeking growth capital, or a mid-cap management team executing an acquisition-led scale-up plan. The firm explicitly emphasizes partnership with management and reinforcing management committees and boards.
Geographic Focus
Primarily Europe, with Paris as headquarters and additional offices in Munich, Antwerp, Milan, Madrid, and (newly opened in September 2026) Frankfurt. andera Life Sciences also invests in the United States. Andera Acto has been expanding into Spain and Italy via senior advisor appointments in 2026.